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Abstract 
Prostate-specific antigen (PSA) testing of men at normal risk of prostate cancer 
is one of the most contested issues in cancer screening. There is no formal 
screening program, but testing is common – arguably a practice that ran ahead 
of the evidence. Public and professional communication about PSA screening 
has been highly varied and potentially confusing for practitioners and patients 
alike. 
There has been much research and policy activity relating to PSA in recent years. 
Landmark randomised controlled trials have reported; authorities – including 
the 2013 Prostate Cancer World Congress, the Prostate Cancer Foundation 
of Australia, Cancer Council Australia, and the National Health and Medical 
Research Council – have made or endorsed public statements and/or issued 
clinical practice guidelines; and the US Preventive Services Task Force is revising 
its recommendations. But disagreement continues. 
The contention is partly over what the new evidence means. It is also a result of 
different valuing and prioritisation of outcomes that are hard to compare: prostate 
cancer deaths prevented (a small and disputed number); prevention of metastatic 
disease (somewhat more common); and side-effects of treatment such as 
incontinence, impotence and bowel trouble (more common again). A sizeable 
proportion of men diagnosed through PSA testing (somewhere between 20% 
and 50%) would never have had prostate cancer symptoms sufficient to prompt 
investigation; many of these men are older, with competing comorbidities. It is a 
complex picture. 
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Key points 
• There is no formal prostate cancer screening 
program, but prostate-specific antigen (PSA) 
testing is common in Australia and some other 
jurisdictions and there are NHMRC approved 
Australian guidelines for PSA testing
• During the past 5 years, new evidence and 
new guidance have been produced regarding 
PSA testing of men at average risk of prostate 
cancer
• Considerable uncertainty and disagreement 
remain about what the evidence shows, and 
about whether asymptomatic men should be 
tested 
• A commonly proposed solution is to ensure 
that men are well informed before they 
decide whether to test, but the complexity, 
uncertainty and very different outcomes being 
weighed up suggest that this would require 
considerable support
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View from a cancer epidemiologist 
– by Bruce K Armstrong
That early detection of disease is good is held as true 
by most health professionals and most people. It is not 
surprising, therefore, that early detection action runs 
ahead of evidence of early detection benefit. This is true 
of all national screening programs for cancers in Australia 
– cervical cancer, breast cancer and colorectal cancer – 
and it is true of prostate cancer, among others, for which 
there is no formal national program. The urges of clinicians 
to find cancer early and of people to avoid death from 
the ‘big C’ are so great that it is also not surprising that 
cancer screening without evidence of benefit persists, 
despite evidence or a strong presumption of harm. The 
principal harms are investigation and sometimes treatment 
based on a false positive test; clinical delay and perhaps 
poorer outcomes after a false negative test; and detection, 
diagnosis and treatment of cancers that would otherwise 
have never affected life or health (overdiagnosis). 
How should public health policy tackle prostate-specific 
antigen (PSA) testing for the early detection of prostate 
cancer? How do we proceed when there is uncertain 
benefit and certain harm, when up to 21% of Australian 
men aged 45–74 participate in screening each year and 
may benefit, and 19% aged over 74 also participate and 
probably won’t? Ban it? Regulate it? Or do nothing? (Note: 
These percentages were calculated from data on claims 
for PSA tests [item number 66655] processed by Medicare 
Australia in 2015–16 [medicarestatistics.humanservices.
gov.au/statistics] and Australian Bureau of Statistics 
tables of estimated resident population by age and sex 
at 30 June 2015 and 30 June 2016 [ABS report series 
3101.0 Australian Demographic Statistics], with the value 
7.5 added to each calculated percentage to correct for the 
effect of Medicare’s ‘episode coning’ policy on recording of 
pathology items claimed for.)
Faced with these choices and the lack of other 
likely action, Cancer Council Australia (CCA) and the 
Prostate Cancer Foundation of Australia (PCFA) chose 
to ‘regulate’ by developing clinical practice guidelines 
for PSA testing and early management of test-detected 
prostate cancer. These nonbinding guidelines aimed “to 
maximise the benefits, if there are benefits, and minimise 
the harms from PSA testing”.1 They were approved by 
Australia’s National Health and Medical Research Council 
on 2 November 2015.1 Early management was included 
because early management decisions can influence the 
realisation of assumed benefits and known harms of PSA 
testing.
The PCFA and CCA expert advisory panel made two 
important early decisions: that a national PSA testing 
program akin to the national breast cancer screening 
program (for example) would not be recommended, and 
that the reported results of the European Randomized 
Study of Screening for Prostate Cancer (ERSPC) 
would provide the evidence base for its PSA testing 
recommendations. The ERSPC is the largest study 
addressing PSA test efficacy, and one of the two largest, 
and the most recent, to report prostate cancer mortality 
reduction in PSA-tested, average-risk men. This was a 
necessary decision because only the ERSPC or statistical 
models based on its results, rightly or wrongly, can inform 
recommendations about the age range for, and frequency 
of, PSA testing, and the PSA level above which further 
investigation is recommended.
The guidelines make no recommendation about 
whether men should be routinely offered PSA testing. Their 
key testing recommendation is: “For men at average risk 
of prostate cancer who have been informed of the benefits 
and harms of testing and who decide to undergo regular 
testing for prostate cancer, offer PSA testing every 2 years 
from age 50 to age 69, and offer further investigation if total 
PSA is greater than 3.0 ng/mL”. Very importantly, they also 
recommend that the responsible clinical practitioner “offer 
evidence-based decisional support to men considering 
whether or not to have a PSA test, including the opportunity 
to discuss the benefits and harms of PSA testing before 
making the decision”. Guidance is given as to how the 
PSA testing recommendation might be modified for 
men at higher than average risk of prostate cancer, and 
recommendations are made on management of men who 
have a PSA >3.0 ng/mL or a biopsy diagnosis of prostate 
cancer, aiming at all times to obtain a balance between the 
benefits hoped for and the possible harms.
Below are four viewpoints from expert participants in the evolving debate, 
commissioned for this cancer screening themed issue of Public Health Research 
& Practice. We asked the authors to respond to the challenge of PSA testing of 
asymptomatic, normal-risk men. They raise important considerations: uncertainty, 
harms, the trustworthiness and interpretation of the evidence, cost (e.g. of using 
multiparametric magnetic resonance imaging to triage patients with elevated 
PSA), a likely bias towards intervention (particularly for cancer), and the potential 
to limit harm by treating more conservatively (although this may not occur 
consistently). They provide important insights, and disagree on some issues, but 
generally concur that men should decide for themselves whether to be tested. 
It seems reasonable to support men’s autonomy to make their own decisions 
based on their own values. However, the support men might require to decide is 
likely to be considerable, and this needs to be taken seriously in policy making.
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There is, as yet, no formal plan to evaluate 
implementation of the guidelines in practice or whether the 
assumed benefits of PSA testing are occurring, or whether 
the benefits are even increasing and harms decreasing. 
We might reasonably hope to see a fall in Australia’s very 
high prostate cancer incidence rates following guideline 
implementation because of a fall in prostate cancer 
overdiagnosis due to the recommended narrower age 
range for, and lower frequency of, PSA testing than has 
been common in recent Australian practice. Because of the 
lack of any recommendation for or against PSA testing, and 
PSA’s uncertain screening efficacy, any prediction of the 
prostate cancer mortality trend would be pure guesswork.
View from the United States – by 
Michael J Barry
There is a lot not to like about screening for prostate cancer 
with the PSA test. In the ERSPC, arguably the highest 
quality trial, although not without its faults2, benefits were 
modest. After 13 years, 1.28 fewer prostate cancer deaths 
per 1000 men were observed with screening, with no 
decrease in overall mortality.3 Heterogeneity among ERSPC 
countries in screening protocols, treatments and outcomes 
has raised questions about the magnitude of benefit 
actually attributable to PSA testing.4 On the other hand, the 
harms of screening are relatively high, with 31 additional 
cases of prostate cancer needing to be detected per 
prostate cancer death prevented.3 Men are not used to 
thinking of PSA screening as ‘causing’ cancer, but, for 
practical purposes, the substantially higher incidence with 
screening means just that. The higher incidence reflects 
more prostate biopsies, with short-term complications 
of haematuria, haematochezia, haematospermia and 
infections. The main harms, however, come from the 
treatment of men found to have prostate cancer, including 
substantial risks of erectile dysfunction and incontinence. 
Most of these cancers are never destined to cause 
morbidity or mortality5, and the men who harbour them 
can only be harmed by early detection. Finally, at least in 
relation to practices in the US, PSA screening is not cost-
effective.6
That all sounds like a pretty good argument for not 
screening, right? Perhaps. However, the absolute benefit 
from prostate cancer screening, if the ERSPC estimate 
is correct, is not dissimilar to the benefit of screening for 
breast cancer, and reducing overall mortality may be too 
high a bar for any screening test. Modelling strategies, and 
the reduction in metastases seen in the ERSPC, suggest 
that the absolute benefit may be greater over a longer 
time. Strategies being considered for maintaining most 
of the benefits while reducing the harms include testing 
less frequently (the screening interval in the ERSPC was 
2–4 years), higher biopsy thresholds and, most importantly, 
active surveillance for men with low-risk cancers. These 
strategies to mitigate harm are not perfect and will come 
at the price of slightly higher risks of bad outcomes. For 
example, in the ProtecT study, active monitoring had the 
same cancer-specific mortality as surgery or radiation 
over 10 years (about 1%) but a higher risk of metastases 
(6% versus 3%).7 Whether these strategies, which may 
make screening cost-effective6, will prove acceptable to 
most clinicians and patients remains to be seen. The most 
important reason for not rejecting PSA screening is that 
there is variation in how men see the trade-offs between 
possible benefits and harms. When men were fully informed 
about the trade-offs in a decision making process including 
a patient decision aid, and could answer key knowledge 
questions accurately, about a third still wanted a PSA test.8 
Key points to cover in a conversation between a man and a 
clinician have been previously reviewed.5
Some health systems will reasonably decide not to 
make PSA screening generally available because their 
limited resources can be used more effectively in other 
ways. However, if PSA screening is available, letting 
informed men help decide whether a PSA test is right for 
them seems the most patient-centred way forward. After 
all, they are the ones who must live with the consequences 
of the decision.
View from urologists – by Mark 
Frydenberg and Robert A Gardiner
Before considering selective screening for prostate cancer, 
the question to be asked is whether a diagnosis will 
benefit the patient. The answer can only be determined 
by establishing whether the patient accepts the risks 
and potential side effects of the diagnostic and treatment 
processes, appreciates the likelihood of cancer (if 
present) to affect his health and wellbeing, and can make 
a value judgement about what is really important to him. 
Consequently, there is no place for mass population or so-
called opportunistic PSA screening.
The large majority of men investigated for prostate 
cancer are asymptomatic and do not have suspected 
malignancy based on a digital rectal examination. Because 
of the long natural history of most tumours, a 7–10year life 
expectancy following treatment (and therefore diagnosis) 
is considered warranted before considering PSA testing. 
Pertinently, many patients have significant or latent 
comorbidities that will significantly affect their survival within 
a decade, so they will not live long enough to achieve a 
survival benefit.9-12 
Serious health problems are not uncommon in middle-
aged and elderly males, along with lifestyle-related factors 
such as smoking and obesity, which have yet to overtly 
affect morbidity and mortality. A poor appreciation of 
individual life expectancy is not just limited to patients, 
as many clinicians are also overoptimistic and give 
patients ‘the benefit of the doubt’ when recommending 
investigations and treatments.12 To introduce some 
objectivity to overall patient prognosis, life expectancy 
tables13,14 may be helpful, although they are population 
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based and do not take into account an individual’s 
comorbidities or sociodemographic factors.
Selective screening involves identifying men who are at 
risk of developing clinically significant prostate cancer, and 
are likely to benefit from a prostate cancer diagnosis and 
therefore PSA testing. As we have previously reported15, 
a family history (particularly in first-degree relatives) is well 
recognised to predispose to a future diagnosis of prostate 
cancer, but a PSA –1.5, 12.4 ng/mL for men aged less 
than 50 years is regarded as even more predictive than 
either family history or ethnicity.16 Hereditary prostate 
cancers occur more commonly than any other tumour 
diagnosed – on average, detected 6 years earlier than for 
sporadic cancer.17 Patients with a family history of germ-line 
mutations in the family-susceptibility genes BRCA1 and 
BRCA2 have a significantly increased risk of developing 
this malignancy, tend to present at a younger age, and 
tend to have more aggressive disease and poorer survival 
outcomes.18–22
Increasingly, multiparametric magnetic resonance 
imaging (mpMRI) is being used to triage patients with an 
elevated PSA. A combination of anatomical (T2-weighted) 
images with at least two of the three functional MRI 
parameters (diffusion-weighted imaging, dynamic contrast-
enhanced imaging and spectroscopy) has been estimated 
to identify approximately 90% of moderate- to high-risk 
lesions, but is less reliable for detecting small (<0.5 cubic 
centimetres) and lower risk tumours.23-25 Limitations to using 
mpMRI are the level of accuracy of MRI interpretation and 
cost. However, until a cheaper and comparably accurate 
diagnostic test replaces PSA testing, the combination of 
PSA testing and mpMRI will remain the initial investigation 
of choice before biopsy. 
It is easy to overlook or underestimate the quality-of-
life impacts, which range from the anguish of possibly 
harbouring a malignancy to the uncommon but potentially 
devastating effects of infection associated with a biopsy, 
to the side-effects of the various treatments. Some men 
may rather risk a cancer spreading (especially in a cancer 
of lower histological grade) and remain untreated than risk 
losing their sexual or urinary abilities, in addition to other 
changes in bodily function that can affect social confidence 
and self-esteem. Consequently, it is imperative at the outset 
to evaluate and respect decisions made with respect to 
quality of life26 when deciding whether to test for prostate 
cancer.
View from an oncologist – by Ian 
Haines
In 2012, the US Preventive Services Task Force (USPSTF) 
downgraded its recommendation for screening using 
PSA testing from C to D.27 Since that advice, the much-
anticipated ProtecT study28 has been published. It 
randomised 1643 men equally between radical surgery, 
radical radiation and active monitoring, and reported results 
at 10 years. It revealed that only 1% of men with early-stage 
prostate cancer died of their disease in the first 10 years 
after diagnosis, irrespective of treatment and the usual 
prognostic factors. 
Although treatment achieved a significant reduction in 
local disease progression and metastases, the lack of a 
significant survival benefit for radical surgery over active 
monitoring confirms the results of the Prostate Cancer 
Intervention Versus Observation Trial (PIVOT), the only other 
randomised trial done in the era of PSA screening tests.29 
It found no significant prostate cancer–specific mortality 
or overall survival benefit for radical surgery over active 
monitoring at 12 years, confirmed at 19.5 years follow-up.30 
PIVOT showed an absolute risk reduction of 5.5% (95% 
confidence interval [CI] –1.15, 12.4%; p = 0.06) for all-cause 
mortality (61.3% in patients treated with prostatectomy 
vs 66.8% in patients who had active monitoring) and 
an absolute risk reduction of 4% (95% CI –0.2%, 8.3%; 
p = 0.06) for prostate cancer–specific mortality (7.4% in 
patients treated with prostatectomy vs 11.4% in patients 
who had active monitoring). Although surgery reduced 
the need for treatment of progressive disease, there were 
increased treatment-related long-term complications such 
as urinary incontinence and erectile dysfunction. The 
dissemination of these results to every man over 40 will aid 
their informed decision making about PSA testing, and may 
reduce the overdiagnosis, overtreatment, and significant 
and immediate physical and psychological harms caused to 
many of them.31
One of the reasons for this widespread testing has been 
that one of the two large randomised studies of screening 
for prostate cancer with PSA, the ERSPC32, showed a 
small survival benefit for screening. However, it has been 
suggested by the chief medical and scientific officer of 
the American Cancer Society that this study has flaws 
and unintended biases, such as a large disparity between 
primary treatment with androgen deprivation monotherapy 
given to similar risk patients in each arm.33 The call for an 
independent review of the mortality data was repeated in 
a recent review.34 Conversely, the other major randomised 
screening study35, which showed no benefit for screening, 
was recently found to have major contamination of the 
control arm, in which 90% of men had a PSA test during 
the study period.36 This makes its results less reliable, 
although it is important to note that there were still 22% 
more cancers diagnosed in the screening arm after 2 years, 
with no associated survival benefit.
Despite the efforts of many urologists to reduce 
overdiagnosis and overtreatment, some urology groups 
suggest that all men over 40 should consider a screening 
PSA test37, even when we know that 24.4% of men with 
a ‘normal’ PSA are diagnosed with prostate cancer when 
they have a biopsy38 and it is a common finding in this age 
group at autopsy.39 Many are advised to consider radical 
treatment, with all the possible adverse consequences, 
for a disease that kills 1 in 7 (2–3% of all men) at a median 
age of 82.440 and for which there is still no proven survival 
benefit for radical intervention. 
This is poor public health policy. The USPSTF should 
not reverse its previous advice.41
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